Future Mpox Outbreaks in England Can be Prevented with Routine Vaccination

Curtailing Diseases Future Mpox Outbreaks in England Can be Prevented with Routine Vaccination

2025-07-04 Source: Press release University of Bristol 3 min Reading Time

Related Vendors

DÜPERTHAL Sicherheitstechnik GmbH & Co. KG

Bimos - eine Marke der Interstuhl Büromöbel GmbH & Co. KG

A new study has revealed that a mpox vaccination routine for gay and bisexual men can greatly reduce the number of mpox cases in England and also save the NHS a lot of money.

A magnified image of the mpox virus.(Source: University of Bristol) — A magnified image of the mpox virus.
(Source: University of Bristol)

Bristol/UK – The study, co-led by the University of Bristol, the UK Health Security Agency (UKHSA), and the National Institute for Health and Care Research (NIHR), evaluated the most cost-effective way to minimize future mpox outbreaks among gay and bisexual men through vaccination.

It found that all vaccination strategies significantly reduced the likelihood of outbreaks and their associated costs while also resulting in improved health-related quality of life among affected groups, compared to no vaccination.

Continuous vaccination, with increased vaccination during outbreaks, was shown to be the most successful strategy offering savings of some 9million pounds and reducing the number of projected cases from 11,000 to 1,000 over ten years.

Joint senior author Peter Vickerman, Professor of Infectious Disease Modelling at the University of Bristol, said: “Our findings highlight the critical role of vaccination in limiting the spread of mpox. Moreover, the study results also illustrate how proactive vaccination in a routine programme for groups at risk of mpox provides better health outcomes and also saves health services a lot of money, so it’s a clear win-win.”

Mpox, previously known as monkeypox, is a viral illness which is most prevalent in parts of central and east Africa.

The researchers, from the National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in Evaluation and Behavioural Science based at the University of Bristol, developed their model using health data from England in 2022, when a global mpox outbreak occurred, mainly affecting gay and bisexual men. In England this outbreak was dramatically reduced through health promotion, changes in sexual behavior, and vaccinating gay and bisexual men at highest risk of infection.

Costs were estimated for case management, vaccination, and public health responses during this outbreak. The researchers used their model to look at what vaccination strategies are needed to prevent future outbreaks, with costs arising from the 2022 outbreak being used to estimate costs of any future outbreaks and continuing vaccination.

Although mpox is rare, there is an expanding outbreak of a strain of mpox called Clade Ib in Sub-Saharan Africa, spread within households, and through close contact including sexual contact.

While the research model focused on transmission within sexual networks of gay and bisexual men, the research team hope to expand the study to consider the impact of, and best way to prevent sustained transmission, in the whole population in England. This would include scenarios where mpox was transmitted through sex between men and women.

Prof Vickerman explained: “Our analyses show that all modelled vaccination strategies are likely to be cost-saving, decrease the number of infections and improve quality of life compared to not vaccinating. Continuous vaccination at a low rate, potentially with increased vaccination during outbreaks, was found to be the most cost-effective strategy. This finding is robust over most sensitivity analyses with mpox vaccination remaining cost-effective below a vaccine price threshold.”

Dr Sema Mandal, Consultant Epidemiologist and Deputy Director of Public Health Programmes at UKHSA, added: “As this study shows, vaccination plays an essential role in helping to reduce mpox cases and preventing future outbreaks.

“With mpox vaccination now available in every region of England for those at increased risk of infection, getting vaccinated is easier than ever before. If you are eligible, please do make sure you have had the vaccine to protect yourself from mpox.”

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

The study was funded by the University of Bristol and UKHSA’s NIHR HPRU in Evaluation and Behavioural Sciences in partnership with University College London and UKHSA’s NIHR HPRU in Blood Borne and Sexually Transmitted Infections.

Paper: ‘Cost-effectiveness of vaccination strategies to control future mpox outbreaks in England: a modelling study’ by Xu-Sheng Zhang et al in The Lancet Regional Health – Europe.

(ID:50472894)